Veraxa Biotech AG Warrants

VRXAW

Capitalización de mercado USD 402 k

Acerca de: Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.